Revising the model for vaccine development: a step towards tuberculosis immunity

Main Article Content

Amy Dagenais

Article Details



1. Government of Canada. Pfizer-BioNTech COVID-19 Vaccine (tozinameran) [Internet]. Government of Canada; [updated 2021 Mar 26; cited 2021 Mar 26]. Available from:
2. World Health Organization. Global tuberculosis report 2020. Geneva (CH): WHO Press; 2020. 232 p. Licence: CC BY-NC-SA 3.0 IGO.
3. Vachon J, Gallant V, Siu W. Tuberculosis in Canada, 2016. CCDR. 2018 Mar 1;44(3/4):75–81.
4. World Health Organization. Global tuberculosis control 2009: epidemiology, strategy, financing. WHO Press; 2009. 314 p. ISBN 978 92 4 156380 2
5. Young C, Walzl G, Du Plessis N. Therapeutic host-directed strategies to improve outcome in tuberculosis. Mucosal Immunol. 2020 Mar;13(2):190–204.
6. World Health Organization. Lack of new antibiotics threatens global efforts to contain drug-resistant infections [Internet]. World Health Organization; 2020 Jan 17 [cited 2021 Mar 26]. Available from:,weak%20pipeline%20for%20antibiotic%20agents
7. Public Health Agency of Canada. Canadian Tuberculosis Standards 7th Edition. Ontario (CA): Government of Canada; 2014. Chapter 16: Bacille Calmette-Guérin (BCG) vaccination in Canada; p. 405.
8. Martin C, Aguilo N, Marinova D, Gonzalo-Asensio J. Update on TB Vaccine Pipeline. Applied Sciences. 2020 Apr 10;10(7):2632.
9. Kovesi T. Respiratory disease in Canadian First Nations and Inuit children. Paediatr Child Health. 2012 Aug 1;17(7):376-380.
10. Patterson M, Flinn S, Barker K. Addressing tuberculosis among Inuit in Canada. CCDR. 2018 Mar 1;44(3/4):82–5.
11. World Health Organization. Coronavirus update 45: Update on COVID-19 vaccine development [Internet]. World Health Organization; [updated 2020 Dec 21; cited 2021 Mar 26]. Available from:
12. Government of Canada. Backgrounder – Government of Canada investments in COVID-19 vaccines, therapeutics and biomanufacturing capacity [Internet]. Government of Canada; 2021 Feb 2 [cited 2021 Mar 26]. Available from:
13. Treatment Action Group. Tuberculosis research funding trends 2005-2019. New York (US); 2020. 62 p.
14. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261–79.
15. Li H, Liu L, Zhang W, Zhang X, Zheng J, Li L, et al. Analysis of the antigenic properties of membrane proteins of Mycobacterium tuberculosis. Sci Rep. 2019 Dec;9(1):3042.